156P - Correlation of baseline value of folate receptor-positive circulating tumor cells and efficacy of pemetrexed and dynamic monitoring study in NSCLC...

Date 15 April 2016
Event European Lung Cancer Conference 2016 (ELCC) 2016
Session Poster lunch
Topics Cytotoxic agents
Translational Research
Non-small-cell lung cancer
Basic Principles in the Management and Treatment (of cancer)
Therapy
Biological therapy
Presenter XiaoXia Chen
Citation Journal of Thoracic Oncology (2016) 11 (supplement 4): S57-S166. S1556-0864(16)X0004-4
Authors X. Chen1, C. Zhou2, X. Li3, G. Yang4
  • 1Medical Oncology And Lung Cancer And Immunology, Shanghai Pulmonary Hospital, Tongji University, 200433 - Shanghai/CN
  • 2Oncology, Shanghai Pulmonary Hospital, Tongji University, 200433 - Shanghai/CN
  • 3Dept. Of Lung Cancer Immunology, Shangai Pulmonary Hospital, Tongji University School of Medicine, 200082 - Shanghai/CN
  • 4Research Department, Genosaber Biotec Co. Ltd, 201203 - Shanghai/CN

Abstract

Background

The efficacy of pemetrexed associates with the expression of folate enzymes, however, few serological marker is available to predict its efficacy. Moreover, dynamic monitoring of CTC count can predict the outcome of tumor therapy and the overall survival of the patient. By quantitative determination of folate receptor-positive CTCs, this study investigated the correlation of its baseline values to the efficacy of pemetrexed and performed a dynamic monitoring study in NSCLC patients who underwent first-line platinum-based chemotherapy.

Methods

This study enrolled 70 NSCLC patients who received first-line platinum-based chemotherapy. The CTCs were quantified by negative enrichment using immunomagnetic beads in combination with folate receptor-directed PCR that allows secondary amplification of tiny amounts of CTCs in peripheral blood. In this study, the CTC levels were examined by collecting 3 mL of anti-EDTA whole blood samples before the treatment and after every chemotherapy, and followed up until progressive disease (PD) or completion of first-line chemotherapy.

Results

Of twenty-two patients who received pemetrexed disodium/platinum combined therapy (AP/AC), the patients harboring high levels of folate receptor showed greater efficacy than those with low expression levels (8.7 

Conclusions

The patients with high expression of folate receptor-positive CTCs appear to have superior response to pemetrexed than those with low expression. Additionally, the changes of CTC count can be used as a dynamic monitoring indicator in the treatment process to evaluate tumor burden and therapeutic outcomes.

Clinical trial identification

Legal entity responsible for the study

Shanghai Pulmonary Hospital, Tongji University of Medicine

Funding

Genosaber Biotech Co.Ltd

Disclosure

All authors have declared no conflicts of interest.